NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Gedea Biotech

Gedea Biotech

Private
LundHealthcare & Life Scienceshttps://gedeabiotech.com/

Last Round

Grant

Feb 29, 2024

Total Funding Raised

$5.03M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Gedea Biotech is a biotechnology company that develops pHyph, an antibiotic-free treatment for vaginal infections.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Medical Devices, Clinical Trials

Business Model

B2B2C

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

bacterial vaginosis treatmentnon-antibiotic treatmentvaginal healthfeminine healthBV treatmentmedical devicetopical treatmentbiotech licensingpharma partnershipfemtechvaginal microbiomeclinical developmentgynecology

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Gedea Biotech Comps

Public and private peers based on sector, stage, and business model.

Gedea Biotech comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Gedea Biotech Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantFeb 29, 2024
VC RoundNov 15, 2023
VC RoundMay 24, 2023
GrantApr 4, 2023
VC RoundOct 28, 2021
Grant
Dec 11, 2019

Key People

Founding team and executive leadership

Annette Säfholm

CEO

Executive Team

Per-Ola Forsberg

Chief Financial Officer

Executive Team

Gedea Biotech Investors

Notable investors and investment history

Gedea Biotech investors
InvestorRounds
European Innovation CouncilGrant
Almi Invest ABSeed
VinnovaGrant
Porte-Monnaie VentureSeed
SwelifeGrant
LU VenturesSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 1, 2026

    Monthly visitors grew 182% MoM, reaching 1.3K.

  • Jan 27, 2026

    Julie Waras Brogren appointed as new CEO.

Gedea Biotech Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Gedea Biotech Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Gedea Biotech's valuation, stock price, and market status.

Firmographic Details

HeadquartersLund
Employee Range16
Year Founded2015
Last FundingFeb 29, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.